Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle–Aged Adults
- Auriel A. Willette, PHD,
- Guofan Xu, MD, PHD,
- Sterling C. Johnson, PHD,
- Alex C. Birdsill, BS,
- Erin M. Jonaitis, PHD,
- Mark A. Sager, MD,
- Bruce P. Hermann, PHD,
- Asenath La Rue, PHD,
- Sanjay Asthana, MD, and
- Barbara B. Bendlin, PHD
Abstract
OBJECTIVE Insulin resistance dysregulates glucose uptake and other functions in brain areas affected by Alzheimer disease. Insulin resistance may play a role in Alzheimer disease etiopathogenesis. This longitudinal study examined whether insulin resistance among late middle–aged, cognitively healthy individuals was associated with 1) less gray matter in Alzheimer disease–sensitive brain regions and 2) worse cognitive performance.
RESEARCH DESIGN AND METHODS Homeostasis model assessment of insulin resistance, gray matter volume, and the Rey Auditory Verbal Learning Test (RAVLT) were acquired in 372 participants at baseline and a consecutive subset of 121 individuals ~4 years later. Voxel-based morphometry and tensor-based morphometry were used, respectively, to test the association of insulin resistance with baseline brain volume and progressive gray matter atrophy.
RESULTS Higher insulin resistance predicted less gray matter at baseline and 4 years later in medial temporal lobe, prefrontal cortices, precuneus, and other parietal gyri. A region-of-interest analysis, independent of the voxel-wise analyses, confirmed that higher insulin resistance was related to medial temporal lobe atrophy. Atrophy itself corresponded to cognitive deficits in the RAVLT. Temporal lobe atrophy that was predicted by higher insulin resistance significantly mediated worse RAVLT encoding performance.
CONCLUSIONS These results suggest that insulin resistance in an asymptomatic, late middle–aged cohort is associated with progressive atrophy in regions affected by early Alzheimer disease. Insulin resistance may also affect the ability to encode episodic information by negatively influencing gray matter volume in medial temporal lobe.
My Beloved, Where are you?
Congratulations on your new Wellness Franchise Owners! (Dealer or Franchise Apply and/or Buy Products) Around the world., Where are you? Referring ID Number or/and Your Enroller's ID or/and Sponsor ID :: 102421666 And Password:: 1024216667 Email::shilohthai@gmail.com
United States of America
Your Enroller's ID or/and Sponsor ID :: 102421666
Your Enroller's ID or/and Sponsor ID :: 102421666
Mexico
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Puerto Rico
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Dominican Republic
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Bahrain
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666 Algeria
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Oman
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Kuwait
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Tunisia
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Egypt
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Jordan
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Lebanon
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Morocco
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Qatar
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666Saudi Arabia
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666United Arab Emirates
Your Enroller’s ID or/and Sponsor ID :: 98649666
Your Enroller’s ID or/and Sponsor ID :: 98649666
ไม่มีความคิดเห็น:
แสดงความคิดเห็น